MediPharm Labs: A Turning Point — Positive Net Income and Breakthrough Dementia Trial Results

First profitable quarter since 2019 and a statistically significant Phase II dementia drug trial validate a slow-burn pivot to pharma.

LABS.TO · Earnings Call · 2026-08-13

MediPharm Labs (LABS.TO) delivered a quarter that feels like a culmination. For the first time since 2019, the company reported positive net income, backed by a second consecutive quarter of positive adjusted EBITDA and a gross margin that hit 43%. But the more consequential news came from the lab, not the ledger: the LiBBY clinical trial, a Phase II placebo-controlled study of its proprietary cannabinoid formulation for agitation in dementia, met its primary endpoint and all key secondary endpoints. For a company that has long marketed itself as a pharmaceutical-grade platform, this is the first hard validation that the platform can produce real clinical results.

A Milestone Quarter

CEO Greg Hunter framed the results bluntly: “Q2 was a significant quarter for MediPharm as we achieved positive net income for the first time since 2019.” — Greg Hunter, Interim CEO and Chief Financial Officer · 2026-08-13 Revenues rose 11% sequentially to $10 million, driven largely by Germany, where international medical cannabis sales grew 45% quarter-over-quarter. The growth was not just volume: gross margin expanded to 43%, among the highest in recent quarters, thanks to a disciplined mix shift toward branded products and continued cost control. Operating expenses fell 44% year-over-year after a restructuring that is expected to generate more than $1 million in annualized savings.

The LiBBY Breakthrough

The LiBBY trial is the most significant event of the quarter. It was a U.S. multi-center, randomized, double-blind, placebo-controlled study enrolling 120 hospice-eligible patients. The results were presented at the Alzheimer’s Association International Conference in July, and Hunter highlighted the durability of the effect:

The study met its primary endpoint and all key secondary endpoints, demonstrating statistically significant improvement in agitation in patients with dementia, with benefits observed as early as 2 weeks and sustained throughout the 12-week treatment period.
Greg Hunter, Interim CEO and Chief Financial Officer · 2026-08-13

Nearly 9 out of 10 treated patients showed overall clinical improvement by week 12. Crucially, the formulation was developed and supplied exclusively by MediPharm, and the company has filed two U.S. provisional patent applications covering the formulation and its therapeutic applications. This is not a repackaging of a known compound; it is proprietary intellectual property emerging from the company’s own R&D. The trial was funded by the National Institute on Aging and the Alzheimer’s Association, and conducted through the NIH-funded Alzheimer’s Clinical Trial Consortium — giving the results immediate credibility. For a micro-cap cannabis company, this is a rare asset: independent, peer-reviewed evidence that its drug candidate works.

Financial Resilience Amid Headwinds

But the quarter was not without challenges. Veterans Affairs Canada cut its reimbursement rate for medical cannabis from $8.50 to $6.00 per gram effective April 1, hitting the domestic medical channel directly. Canadian medical revenue fell from $3 million to $2.3 million quarter-over-quarter. Hunter acknowledged the impact but stressed the mitigating actions: cost reductions, procurement efficiency, and product mix optimization. The company still delivered positive net income and its best adjusted EBITDA since 2019. International business continues to be the growth engine, with Germany, France, Brazil, and New Zealand all contributing. Germany alone grew 45% sequentially, and branded sales more than doubled. Hunter was candid about rising competition and regulatory scrutiny in Germany, but he framed it as an advantage: "Regulatory is in our DNA."

Contrast with the Past

This is a different company than the one that reported a year ago. In the prior calls, the narrative was about international expansion, market entries, and EBITDA losses. There was no mention of dementia, agitation, or a proprietary drug candidate. The keyword trajectory for 2026 Q3 is dominated by patients with dementia, pharmaceutical platform, and reimbursement changes — none of which appeared in any prior quarter’s top keywords. In the 2024 call, Keith Strachan said, “Germany has been exciting this year as we saw the changes come into effect in April with the removal of the narcotics.” — Keith Strachan, Chief Executive Officer · 2024-08-14 That was about market mechanics; today the conversation is about clinical evidence and intellectual property. Even the VAC headwind was discussed more hopefully than before: “We anticipated this change coming and prepared. implementing mitigation efforts.” — Greg Hunter, Interim CEO and Chief Financial Officer · 2026-05-13 That was the old normal. The new normal is positive net income and a dosed-to-proof drug candidate.

Why It Matters

MediPharm Labs is a tiny company with a market cap around $34 million, but the LiBBY results are outsized in their implications. If the Phase II data hold up in Phase III, the company owns a patent-protected formulation for one of the most burdensome symptoms of dementia — an indication with no approved therapies for agitation. The company already has the pharmaceutical licenses, EU GMP certification, and an FDA-inspected facility to eventually manufacture and commercialize it. Even if the odds of approval are long, the optionality is real. For investors, this quarter represents a genuine inflection: the first profitable quarter, a validated clinical asset, and a clear strategic direction. It is also a reminder that in the cannabis sector, where most companies have been trapped in commodity markets, building a regulated pharmaceutical platform can be a differentiator. MediPharm is still not a safe bet, but for the first time in years, it is a compelling story — and the evidence is on the table.